Aptevo announced preliminary Q3'19 product revenue for its Hemophilia B drug IXINITY will be about $9M.
This is a very important development because it represents a 22% sequential increase and 55% Y/Y increase. It also means traction is gaining momentum.
This also means Aprtevo might be very close to being cash flow positive over the next 12 months.
And as I have said in previous articles, this might also mean APVO shares might become a never-expiring option on the company's pipeline.
APVO shares have the potential for a tenfold increase based on IXINITY revenue alone.